2-(三氟甲基磺酰氧基)-1-环戊烯-1-甲酸乙酯 | 122539-74-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机磺酸及其衍生物
• 中文名称: 2-(三氟甲基磺酰氧基)-1-环戊烯-1-甲酸乙酯
• 中文别名: 2-(((三氟甲基)磺酰基)氧基)-1-环戊烯羧酸乙酯
• 英文名称: 2-trifluoromethanesulfonyloxy-cyclopent-1-enecarboxylic acid ethyl ester
• 英文别名: ethyl 2-[[(trifluoromethyl)sulfonyl]oxy]-1-cyclopentene-1-carboxylate；ethyl 2-(trifluoromethanesulfonyloxy)-1-cyclopentenecarboxylate；ethyl 2-{[(trifluoromethyl)sulfonyl]oxy}cyclopent-1-ene-1-carboxylate；ethyl 2-(trifluoromethanesulfonyloxy)-1-cyclopentene-1-carboxylate；1-(trifluoromethylsulfonyloxy)cyclopent-1-ene-2-carboxylic acid-ethyl ester；Ethyl 2-(((trifluoromethyl)sulfonyl)oxy)cyclopent-1-enecarboxylate；ethyl 2-(trifluoromethylsulfonyloxy)cyclopentene-1-carboxylate
• CAS: 122539-74-6
• 化学式: C₉H₁₁F₃O₅S
• mdl: MFCD00209586
• 分子量: 288.245
• InChiKey: ZFLPJHGXVFJDCI-UHFFFAOYSA-N

物化性质

• 沸点：
  74 °C/0.5 mmHg(lit.)
• 密度：
  1.35 g/mL at 25 °C(lit.)
• 闪点：
  113 °C

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.666
• 拓扑面积：
  78
• 氢给体数：
  0
• 氢受体数：
  8

安全信息

• 危险品标志：
  Xi
• 危险类别码：
  R36/37/38
• 海关编码：
  2916209090
• 安全说明：
  S26,S36

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Ethyl 2-(trifluoromethylsulfonyloxy)cyclopent-1-enecarboxylate
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Ethyl 2-(trifluoromethylsulfonyloxy)cyclopent-1-enecarboxylate
CAS number: 122539-74-6

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C9H11F3O5S
Molecular weight: 288.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen fluoride, sulfur oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-(三氟甲基磺酰氧基)-1-环戊烯-1-甲酸乙酯 在 bis-triphenylphosphine-palladium(II) chloride 、 lithium hydroxide 、 copper(l) iodide 、 叠氮磷酸二苯酯 、 N,N-二异丙基乙胺 作用下， 以 邻二氯苯 为溶剂， 反应 5.0h， 生成 4-Methyl-2,3,4,6,7,8-hexahydro-1H-9-oxa-4-aza-cyclopenta[a]naphthalen-5-one
  参考文献：
  名称：

  烯类异氰酸酯热解的双自由基/两性离子。在2（1 H）-吡啶酮，苯并呋喃[3,2 - c ]吡啶-1（2 H）-，2,5-二氢-1H-吡啶[4,3- b ]吲哚-的合成中的应用1-one和相关化合物

  摘要：

  苯甲环化的烯炔异氰酸酯13和烯炔异氰酸酯36和37的热分解促进了环芳构化反应，从而分别在原位生成O，4-二氢-2-羟基喹啉和O，4-二氢-2-羟基吡啶作为反应中间体。这些环芳基化的中间体可被捕获为双自由基和/或两性离子，这取决于炔基末端的取代基的性质。可以将带有苯基取代基的13a环芳构化衍生的中间体视为双自由基14，然后从γ-萜品烯中提取氢原子，生成2（1 H）-喹啉酮15。或者，同一中间体也可被视为两性离子14 '，然后将其从γ-萜品烯中提取氢化物，然后进行质子化反应生成15。的存在下，2-苯乙基取代基在13B和37A或在2-甲基取代基37B也允许所得到的中间体的分子内或者被捕捉为双自由基或作为两性离子，制备2-（1 ħ） -喹啉酮19，2（1个ħ）-吡啶酮39和苯并吡喃吡啶43， 分别。另一方面，对于2-甲氧基苯基，2-（二甲基氨基）苯基或3-甲氧基丙基取代基，可以用两性离子中间体生成

  DOI：

  10.1021/jo049716t
• 作为产物：
  描述：

  2-氧代环戊羧酸乙酯 在 trifluoromethanesulfonic acid anhydride 作用下， 以 二氯甲烷 为溶剂， 以96%的产率得到2-(三氟甲基磺酰氧基)-1-环戊烯-1-甲酸乙酯
  参考文献：
  名称：

  Cycloalkenyl substituted compounds

  摘要：

  用于治疗的新型吡啶基或嘧啶基取代的环烯基化合物和组合物。

  公开号：

  US06362193B1

文献信息

• HEPATITIS C VIRUS INHIBITORS AND USES THEREOF IN PREPARATION OF DRUGS
  申请人：CHANGZHOU YINSHENG PHARMACEUTICAL CO., LTD.

  公开号：US20170253614A1

  公开（公告）日：2017-09-07

  A series of hepatitis C virus (HCV) inhibitors and compositions and applications thereof in the preparation of drugs for treating chronic HCV infection. Especially, a series of compounds that are used as NS5A inhibitors, and compositions and uses thereof in the preparations of drugs.

  一系列丙型肝炎病毒（HCV）抑制剂及其组合物，以及在制备用于治疗慢性HCV感染的药物时的应用。特别是一系列用作NS5A抑制剂的化合物，以及在药物制剂中的组合物和用途。
• Expedient Synthesis of Highly Substituted Fused Heterocoumarins
  作者：P. Sellès、U. Mueller

  DOI：10.1021/ol0362461

  日期：2004.1.1

  [reaction: see text] Highly substituted fused coumarins can be prepared in two steps starting from the appropriate boronic acids and enol triflates. The synthesis of fused pyrano[2,3-d]pyrimidin-7-one (1) is a key example to demonstrate the potential of the method in the elaboration of new coumarin scaffolds.

  [反应：见正文]可以从适当的硼酸和烯醇三氟甲磺酸酯开始，分两步制备高度取代的稠合香豆素。融合的吡喃并[2,3-d]嘧啶-7-一（1）的合成是一个关键实例，证明了该方法在精制新香豆素支架中的潜力。
• Compounds for the treatment of premature ejaculation
  申请人：——

  公开号：US20040063768A1

  公开（公告）日：2004-04-01

  The present invention relates to compounds of Formula (I) and pharmaceutically acceptable salts or solvates thereof and pharmaceutically acceptable formulations comprising said compounds 1 useful for the treatment of premature ejaculation, depression, attention deficit hyperactivity disorder, obsessive-compulsive disorder, post-traumatic stress disorder and substance abuse disorders.

  本发明涉及式(I)化合物及其药用可接受的盐或溶剂化物，以及包含所述化合物的药用可接受配方，用于治疗早泄、抑郁症、注意力缺陷/多动症、强迫症、创伤后应激障碍和物质滥用障碍。
• Palladium-Catalyzed Synthesis of <i>N</i>-Vinyl Pyrroles and Indoles
  作者：Mohammad Movassaghi、Alison E. Ondrus

  DOI：10.1021/jo051450i

  日期：2005.10.1

  azaheterocycles with vinyl triflates is described. Cyclic and acyclic vinyl triflates along with nonnucleophilic azaheterocycles were found to be substrates for this palladium-catalyzed synthesis of N-vinyl pyrrole and indole derivatives.

  描述了具有乙烯基三氟甲磺酸酯的氮杂杂环的立体有规钯催化的N-乙烯基化。发现环状和无环乙烯基三氟甲磺酸酯以及非亲核氮杂杂环是该钯催化的N-乙烯基吡咯和吲哚衍生物的合成的底物。
• [EN] SYNTHESIS METHOD AND INTERMEDIATES USEFUL IN THE PREPARATION OF PYRROLOBENZODIAZEPINES<br/>[FR] PROCÉDÉ DE SYNTHÈSE ET INTERMÉDIAIRES POUVANT SERVIR À PRÉPARER DES PYRROLOBENZODIAZÉPINES
  申请人：SPIROGEN SARL

  公开号：WO2013053872A1

  公开（公告）日：2013-04-18

  A compound of formula I wherein: R7 is selected from: ORA, where RA is selected from C1-4 saturated alkyl, optionally substituted by phenyl, which may bear a chloro substituent, pyridyl and furanyl; chloro; NH2; -CH2-O-C(=O)Me; R8 is OProt°, where Prot° is a silicon-based oxygen protecting group orthogonal to Rc; R9 is selected from H, methyl and methoxy; Rs is selected from CF3, (CF2)3CF3, CH3 and (formula 2) and Rc is selected from: (i) -C(=O)-ORC1, where RC1 is a saturated C1-4 alkyl group; (ii) -CH2-O-C(=0)RC2, where RC2 is methyl or phenyl; (iii) -CH2-O-Si-(RSi1)(RSi2)(RSi3), where RSi1, RSi2, RSi3 are independently selected from C1-6 a saturated alkyl group and a phenyl group; and (iv) -C(-YRC3)(-YRC4) where each Y is independently O or S, and where RC3 and RC4 are independently a saturated C1-4 alkyl group, or together form a C2-3 alkylene.

  式I的化合物，其中：R7选自：ORA，其中RA选自C1-4饱和烷基，可选择地被苯基取代，该苯基可能带有氯取代基，吡啶基和呋喃基；氯；NH2；-CH2-O-C(=O)Me；R8为OProt°，其中Prot°是与Rc正交的基于硅的氧保护基团；R9选自H，甲基和甲氧基；Rs选自CF3，(CF2)3CF3，CH3和（式2）；Rc选自：(i)-C(=O)-ORC1，其中RC1是饱和的C1-4烷基基团；(ii)-CH2-O-C(=0)RC2，其中RC2是甲基或苯基；(iii)-CH2-O-Si-(RSi1)(RSi2)(RSi3)，其中RSi1，RSi2，RSi3分别选自C1-6饱和烷基和苯基；以及(iv)-C(-YRC3)(-YRC4)，其中每个Y独立地为O或S，且RC3和RC4独立地为饱和的C1-4烷基基团，或者一起形成C2-3亚烷基。